期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 7, 期 3, 页码 170-180出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758834015571111
关键词
inhibition; MEK; PI3K; solid tumors; targeted therapy
类别
资金
- Cancer Society of Northern Finland
- Emil Aaltonen Foundation
- Finnish Foundation for Tuberculosis Resistance
- Finnish Oncological Society
- Oulu University Hospital
- Orion-Farmos Science Foundation
- Sigrid Juselius Foundation
- Thelma Makikyro foundation
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to these pathways for cancer therapy. Unfortunately, the antitumor activities of single-agent therapies have generally been disappointing, excluding B-Raf mutant melanoma and renal cell cancer. Preclinical studies have suggested that concurrent targeting of the PI3K-AKT-mTOR and Ras-Raf-MEK-ERK pathways is an active combination in various solid malignancies. In the current work, we review the preclinical data of the PI3K and MEK dual targeting as a cancer therapy and the results of early-phase clinical trials, and propose future directions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据